Corbion Purac announces the acquisition of the lactic acid business of Malladi Specialties Limited.

Today, Corbion Purac and Malladi Specialties Limited (MSL) signed an acquisition agreement to close on October 9th, 2015.

MSL is a leading manufacturer in India of lactic acid and lactic acid based derivatives such as calcium lactate, sodium lactate and buffered lactic acid and supplies the pharmaceutical, home & personal care, chemical and food industries in India. MSL is a Malladi Group Company, one of India's leading pharmaceutical companies.

The transaction includes the sales and delivery of lactic acid and lactic acid based derivatives in India. No production facilities will be acquired. Production will remain with Malladi Drugs and Pharmaceuticals Limited (MDPL), also part of the Malladi Group, which will produce derivatives on behalf of Corbion Purac. MDPL is one of India's leading pharmaceuticals manufacturing Company with a global presence. This transaction allows for a local production base through the partnership, while maintaining control on quality supplied to our customers. Corbion Purac has acquired the lactic acid business for an undisclosed amount.

Frank Goovaerts, Regional Vice President , Corbion Purac Asia Pacific: "For over 80 years Corbion Purac has been an established name and superior service provider in the food and pharmaceutical industry with lactic acid and its derivatives. MSL has a very strong customer base and distribution network in India. This acquisition will enable Corbion to grow its distribution network and customer service in India even further"

see more on
http://www.malladi.co.in/

Malladi Drugs & Pharmaceuticals Ltd is one of India 's most tradition conscious and ethically sound Pharmaceutical Company. Malladi Drugs was founded in 1980 by late
Mr. M L N Sastry, a pioneering microbiologist with expertise in fermentation technology.

Today, Malladi is the leading manufacturer of Active Pharmaceutical Ingredients (API) in the Cough and Cold segment along with a dominant presence in other therapeutic segments like Anti-histamines, Anti-convulsants, Anti-depressants and Anxiolytics (CNS) of the global pharmaceutical industry.

Some of our noteworthy achievements are

•
The first company in India to manufacture Ephedrine & Pseudoephedrine salts through a fully indigenous process.
•
The first Indian company to acquire an API manufacturing facility out of India – Novus Fine Chemicals in New Jersey, USA.
•
We currently market our products in over 60 Countries and are supported by highly motivated and talented partners.

At the heart of this pharmaceutical company there is desire to heal and contribute to the wellness of mankind. We are constantly innovating; Providing Value added services and always ensure that we have excellent relationships with everyone which encompasses our businesses and beyond.

Transacties in aandelen Corbion
d.d. prijs 17.30 uur omzet aantal transacties idem na 17.35.03 uur en latere.
28/9 EUR 19,97 73.758 701 EUR 19,94 85.544 754
29/9 EUR 19,875 73.748 785 EUR 19,87 83.578 847
30/9 EUR 20,445 93.510 715 EUR 20.50 167.395 817 17.35.28 pas notering
1/10 EUR 20,535 137.681 1.217 EUR 20,50 153.929 1.287 17.35.27 gesl.
2/10 EUR 20,49 65.819 646 EUR 20,53 85.441 707 17.35.21 gesl.

23-Sep-2015 1.000 € 19,90 € 19.903,75
24-Sep-2015 2.500 € 19,78 € 49.458,22
25-Sep-2015 5.000 € 20,33 € 101.672,30
28-Sep-2015 10.000 € 20,05 € 200.475,00
29-Sep-2015 2.100 € 19,76 € 41.498,94
30-Sep-2015 5.611 € 20,24 € 113.561,59
Total 2.657.796 € 18,81 € 50.000.004,74

Corbion maakt bekend dat de onderneming het op 2 maart 2015 gestarte aandeleninkoopprogramma ten bedrage van € 50 miljoen heeft afgerond.
In het kader van dit programma zijn in totaal 2.487.296 gewone aandelen voor een
volumegewogen gemiddelde prijs van € 18,4940 per aandeel (totale waarde: € 46,0 miljoen) ingekocht alsook 170.500 financieringspreferente aandelen (serie FPA, FPB en FPC) tegen nominale waarde (totale waarde: € 4,0 miljoen). Alle ingekochte aandelen worden voor het einde van 2015 "ingetrokken".
Het aandeleninkoopprogramma was onderdeel van Corbions toezegging om in 2015
€ 100 miljoen aan haar aandeelhouders uit te keren via enerzijds een extra dividend in contanten ten bedrage van € 50 miljoen en anderzijds de inkoop van eigen aandelen voor een bedrag van € 50 miljoen, zoals gecommuniceerd tijdens de Strategy Update (‘Disciplined Value Creation’) op 30 oktober 2014.
Periodiek zal Corbion haar schuldpositie in relatie tot de investeringsplannen beoordelen en besluiten over eventuele verdere uitkeringen.

reactie
XEA.nl
Nu het inkoopprogramma is voltooid zien wij de weg naar een overname van Corbion duidelijker aanwezig komen/worden.
Minder aandelen door de overnemende partij te betalen en hetzelfde bedrijf binnenhalen.
Waarom de laatste tijd zoveel grote omzetten in de laatste 5 spookminuten? Toeval? Dat bestaat tegenwoordig niet meer.